Evidence map›Paper›PMID 36187008›Full record

ArticleFrontiers in cardiovascular medicine2022

Robust therapeutic effects on COVID-19 of novel small molecules: Alleviation of SARS-CoV-2 S protein induction of ACE2/TMPRSS2, NOX2/ROS, and MCP-1.

Ji Youn Youn, Jian Wang, Qian Li, Kai Huang, Hua Cai

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Cross-Talk of NADPH Oxidases and Inflammation in Obesity.Antioxidants (Basel, Switzerland) · 2023
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Ji Youn YounDivision of Molecular Medicine, Department of Anesthesiology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, United State.
Jian WangDepartment of Cardiology, China-Japan Friendship Hospital, Beijing, China.
Qian LiDivision of Molecular Medicine, Department of Anesthesiology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, United State.
Kai HuangDivision of Molecular Medicine, Department of Anesthesiology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, United State.
Hua CaiDivision of Molecular Medicine, Department of Anesthesiology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, United State.
University of California, Los Angeles · USChina-Japan Friendship Hospital · CN

Funding

Angiotensin II Uncoupling of Enos in HypertensionR01HL077440 · NHLBI · UNIVERSITY OF CHICAGO · PI CAI, HUA LINDA · 2005 to 2019
$4.8M
NOXs, eNOS Uncoupling and Diabetic AtherogenesisR01HL088975 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CAI, HUA LINDA · 2010 to 2019
$4.5M
Targeting NOX4-dependent mitochondrial dysfunction, autophagy and defective calcium handling in AFR01HL162407 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CAI, HUA LINDA, GOLDHABER, JOSHUA I · 2022 to 2025
$2.8M
Phenotypes and mechanisms of pulmonary hypertension-driven cognitive impairment and Alzheimer's diseaseR01HL154754 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CAI, HUA LINDA, MAKINO, AYAKO · 2020 to 2023
$2.5M
Netrin-1 and Netrin-1 Preconditioned EPCs in Vascular ProtectionR01HL142951 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CAI, HUA LINDA · 2020 to 2023
$2.0M
NHLBI NIH HHS R01 HL077440NHLBI NIH HHS R01 HL088975NHLBI NIH HHS R01 HL142951NHLBI NIH HHS R01 HL154754NHLBI NIH HHS R01 HL162407
6 · The paper itself

Abstract

While new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constantly emerge to prolong the pandemic of COVID-19, robust and safe therapeutics are in urgent need. During the previous and ongoing fight against the pandemic in China, Traditional Chinese Medicine (TCM) has proven to be markedly effective in treating COVID-19. Among active ingredients of TCM recipes, small molecules such as quercetin, glabridin, gallic acid, and chrysoeriol have been predicted to target viral receptor angiotensin-converting enzyme 2 (ACE2)

Indexed as

acute respiratory distress syndrome (ARDS)COVID-19endothelial dysfunctionNADPH oxidase isoform 2 (NOX2)SARS-CoV-2

Identifiers

PMID36187008
PMCPMC9520320
OpenAlexW4296095601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.